Developing strategies to regulate the PPARδ and BCL6 activity to promote the reparative effects of IL-23 and IL-22 may be a novel treatment strategy for restoring barrier integrity and slowing diet-driven IBD occurrence and progression. The gene discussed is IL23A; the disease is inflammatory bowel disease.